Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

No answer to the lack of specificity: mouse monoclonal antibody targeting the angiotensin II type 1 receptor AT1 fails to recognize its target

No answer to the lack of specificity: mouse monoclonal antibody targeting the angiotensin II type... Numerous antibodies targeting G protein-coupled receptors (GPCRs) have been described as non-specific among the polyclonal antibodies against angiotensin II type 1 receptor (AT1). We have tested the newly developed AT1 receptor mouse monoclonal antibody for its specificity. Human embryonic kidney (HEK293) cells, which do not endogenously express AT1 receptor, were transfected in order to overexpress a fluorescently labeled enhanced green fluorescent protein (EGFP)-tagged human AT1 receptor. Western blot and immunofluorescence assays were performed to test the specificity of the Santa Cruz monoclonal antibody sc-57036. These results were compared to the ones obtained with the polyclonal sc-1173 anti-AT1 receptor antibodies that have already been described as non-specific. While the positive controls using GFP antibodies detected the EGFP-tagged AT1 receptor, both polyclonal and monoclonal anti-AT1 receptor antibodies failed to specifically recognize the corresponding band by Western blot, as similar bands were revealed in either transfected or non-transfected cells. It also failed to detect AT1 receptor in immunofluorescence experiments. The lack of target recognition of the monoclonal AT1 receptor antibody in our experimental conditions suggests that this antibody could give misleading results such as misidentification of the protein. To our knowledge, no specific antibodies targeting AT1 receptors have been developed so far and the field is thus in need of new technical developments. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Naunyn-Schmiedeberg's Archives of Pharmacology Springer Journals

No answer to the lack of specificity: mouse monoclonal antibody targeting the angiotensin II type 1 receptor AT1 fails to recognize its target

Download PDF
7 pages

Loading next page...
 
/lp/springer_journal/no-answer-to-the-lack-of-specificity-mouse-monoclonal-antibody-HbBv7GNf0m
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Biomedicine; Pharmacology/Toxicology; Neurosciences
ISSN
0028-1298
eISSN
1432-1912
DOI
10.1007/s00210-018-1522-4
pmid
29868927
Publisher site
See Article on Publisher Site

Abstract

Numerous antibodies targeting G protein-coupled receptors (GPCRs) have been described as non-specific among the polyclonal antibodies against angiotensin II type 1 receptor (AT1). We have tested the newly developed AT1 receptor mouse monoclonal antibody for its specificity. Human embryonic kidney (HEK293) cells, which do not endogenously express AT1 receptor, were transfected in order to overexpress a fluorescently labeled enhanced green fluorescent protein (EGFP)-tagged human AT1 receptor. Western blot and immunofluorescence assays were performed to test the specificity of the Santa Cruz monoclonal antibody sc-57036. These results were compared to the ones obtained with the polyclonal sc-1173 anti-AT1 receptor antibodies that have already been described as non-specific. While the positive controls using GFP antibodies detected the EGFP-tagged AT1 receptor, both polyclonal and monoclonal anti-AT1 receptor antibodies failed to specifically recognize the corresponding band by Western blot, as similar bands were revealed in either transfected or non-transfected cells. It also failed to detect AT1 receptor in immunofluorescence experiments. The lack of target recognition of the monoclonal AT1 receptor antibody in our experimental conditions suggests that this antibody could give misleading results such as misidentification of the protein. To our knowledge, no specific antibodies targeting AT1 receptors have been developed so far and the field is thus in need of new technical developments.

Journal

Naunyn-Schmiedeberg's Archives of Pharmacology – Springer Journals

Published: Jun 4, 2018

References

  • Sorbitane monostearate and cholesterol based niosomes for oral delivery of telmisartan
    Ahad, A; Raish, M; Al-Jenoobi, FI; Al-Mohizea, AM
  • Commercially available antibodies against human and murine histamine H-receptor lack specificity
    Beermann, S; Seifert, R; Neumann, D
  • Six commercially available angiotensin II AT1 receptor antibodies are non-specific
    Benicky, J; Hafko, R; Sanchez-Lemus, E; Aguilera, G; Saavedra, JM
  • Should we be cautious on the use of commercially available antibodies to dopamine receptors?
    Bodei, S; Arrighi, N; Spano, P; Sigala, S
  • Evaluation of the specificity of antibodies raised against cannabinoid receptor type 2 in the mouse retina
    Cécyre, B; Thomas, S; Ptito, M; Casanova, C; Bouchard, JF
  • Inhibition of angiotension II type 1 receptor reduced human endothelial inflammation induced by low shear stress
    Chao, Y; Zhu, L; Qu, X; Zhang, J; Zhang, J; Kong, X; Gu, Y; Pu, J; Wu, W; Ye, P; Luo, J; Yang, H; Chen, S
  • Luminal ANG II is internalized as a complex with AT1R/AT2R heterodimers to target endoplasmic reticulum in LLC-PK1cells
    Ferrão, FM; Cardoso, LHD; Drummond, HA; Li, XC; Zhuo, JL; Gomes, DS; Lara, LS; Vieyra, A; Lowe, J
  • Angiotensin II dependent cardiac remodeling in the eel Anguilla anguilla involves the NOS/NO system
    Filice, M; Amelio, D; Garofalo, F; David, S; Fucarino, A; Jensen, FB; Imbrogno, S; Cerra, MC
  • Commercially available angiotensin II At2 receptor antibodies are nonspecific
    Hafko, R; Villapol, S; Nostramo, R; Symes, A; Sabban, EL; Inagami, T; Saavedra, JM
  • Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein
    Herrera, M; Sparks, MA; Alfonso-Pecchio, AR; Harrison-Bernard, LM; Coffman, TM
  • Angiotensin II promotes pulmonary metastasis of melanoma through the activation of adhesion molecules in vascular endothelial cells
    Ishikane, S; Hosoda, H; Nojiri, T; Tokudome, T; Mizutani, T; Miura, K; Akitake, Y; Kimura, T; Imamichi, Y; Kawabe, S; Toyohira, Y; Yanagihara, N; Takahashi-Yanaga, F; Miyazato, M; Miyamoto, K; Kangawa, K
  • Neuropeptide Y receptor mediates activation of ERK1/2 via transactivation of the IGF receptor
    Lecat, S; Belemnaba, L; Galzi, J-L; Bucher, B
  • Arrestin-biased AT1R agonism induces acute catecholamine secretion through TRPC3 coupling
    Liu, C-H; Gong, Z; Liang, Z-L; Liu, ZX; Yang, F; Sun, YJ; Ma, ML; Wang, YJ; Ji, CR; Wang, YH; Wang, MJ; Cui, FA; Lin, A; Zheng, WS; He, DF; Qu, CX; Xiao, P; Liu, CY; Thomsen, ARB; Joseph Cahill, T; Kahsai, AW; Yi, F; Xiao, KH; Xue, T; Zhou, Z; Yu, X; Sun, JP
  • Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo
    Maussang, D; Mujić-Delić, A; Descamps, FJ; Stortelers, C; Vanlandschoot, P; Stigter-van Walsum, M; Vischer, HF; van Roy, M; Vosjan, M; Gonzalez-Pajuelo, M; van Dongen, GAMS; Merchiers, P; van Rompaey, P; Smit, MJ
  • How reliable are G-protein-coupled receptor antibodies?
    Michel, MC; Wieland, T; Tsujimoto, G
  • Estradiol increases proteinuria and angiotensin II type 1 receptor in kidneys of rats receiving L-NAME and angiotensin II
    Oestreicher, EM; Guo, C; Seely, EW; Kikuchi, T; Martinez-Vasquez, D; Jonasson, L; Yao, T; Burr, D; Mayoral, S; Roubsanthisuk, W; Ricchiuti, V; Adler, GK
  • Structure of a nanobody-stabilized active state of the β2 adrenoceptor
    Rasmussen, SGF; Choi, HJ; Fung, JJ; Pardon, E; Casarosa, P; Chae, PS; DeVree, BT; Rosenbaum, DM; Thian, FS; Kobilka, TS; Schnapp, A; Konetzki, I; Sunahara, RK; Gellman, SH; Pautsch, A; Steyaert, J; Weis, WI; Kobilka, BK
  • Perinatal α-tocopherol overload programs alterations in kidney development and renal angiotensin II signaling pathways at birth and at juvenile age: mechanisms underlying the development of elevated blood pressure
    Ribeiro, VS; Cabral, EV; Vieira, LD; Aires, RS; Farias, JS; Muzi-Filho, H; Vieyra, A; Paixão, AD
  • Mercury-induced vascular dysfunction is mediated by angiotensin II AT-1 receptor upregulation
    Rizzetti, DA; Silva, TM; Escobar, AG; Piagette, J; Peçanha, FM; Vassallo, DV; Alonso, MJ; Salaices, M; Wiggers, GA
  • Nongenomic action of aldosterone on colocalization of angiotensin II type 1 and type 2 receptors in rat kidney
    Sinphitukkul, K; Manotham, K; Eiam-Ong, S; Eiam-Ong, S
  • Early treatment with enalapril and later renal injury in programmed obese adult rats
    Yim, HE; Yoo, KH; Bae, IS; Hong, YS
  • Differential contribution of transmembrane domains IV, V, VI, and VII to human angiotensin II type 1 receptor homomer formation
    Young, BM; Nguyen, E; Chedrawe, MAJ; Rainey, JK; Dupré, DJ
  • Lack of specificity shown by P2Y6 receptor antibodies
    Yu, W; Hill, WG
  • Renal transplantation increases angiotensin II receptor-mediated vascular contractility associated with changes of epigenetic mechanisms
    Zhao, Y; Zhu, Q; Sun, S; Qiu, Y; Li, J; Liu, W; Yuan, G; Ma, H